Long-lasting recombinant factor VIII proteins for hemophilia A
Tóm tắt
In the past 50 years, the lifespan of an individual affected with severe hemophilia A has increased from a mere 20 years to near that of the general unaffected population. These advances are the result of and parallel advances in the development and manufacture of replacement therapies. We are now poised to witness further technologic leaps with the development of longer-lasting replacement therapies, some of which are likely to be approved for market shortly. Prophylactic therapy is currently the standard of care for young children with severe hemophilia A, yet requires frequent infusion to achieve optimal results. Longer-lasting products will transform our ability to deliver prophylaxis, especially in very young children. Longer-lasting replacement therapies will require changes to our current treatment plans including those for acute bleeding, prophylaxis, surgical interventions, and even perhaps immunotolerance induction. Ongoing observation will be required to determine the full clinical impact of this new class of products.
Từ khóa
Tài liệu tham khảo
Larsson, 1985, Life expectancy of Swedish haemophiliacs, 1831-1980, Br J Haematol, 59, 593, 10.1111/j.1365-2141.1985.tb07353.x
Plug, 2006, Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study, J Thromb Haemost, 4, 510, 10.1111/j.1538-7836.2006.01808.x
Darby, 2007, Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV, Blood, 110, 815, 10.1182/blood-2006-10-050435
Kingdon, 2002, An adventure in biotechnology: the development of haemophilia A therapeutics - from whole-blood transfusion to recombinant DNA to gene therapy, Biotechnol Appl Biochem, 35, 141, 10.1042/BA20010082
Srivastava, 2013, Guidelines for the management of hemophilia, Haemophilia, 19, e1, 10.1111/j.1365-2516.2012.02909.x
Simpson, 2012, Management of joint bleeding in hemophilia, Expert Rev Hematol, 5, 459, 10.1586/ehm.12.27
Kauvar, 2006, Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations, J Trauma, 60, S3, 10.1097/01.ta.0000199961.02677.19
Manco-Johnson, 2007, Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia, N Engl J Med, 357, 535, 10.1056/NEJMoa067659
Ahnström, 2004, A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia, Haemophilia, 10, 689, 10.1111/j.1365-2516.2004.01036.x
Collins, 2010, Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens, J Thromb Haemost, 8, 269, 10.1111/j.1538-7836.2009.03703.x
Ewenstein, 2004, Consensus recommendations for use of central venous access devices in haemophilia, Haemophilia, 10, 629, 10.1111/j.1365-2516.2004.00943.x
Thornburg, 2009, Prophylactic factor infusions for patients with hemophilia: challenges with treatment adherence, JCD, 1
Schrijvers, 2013, Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review, Haemophilia, 19, 355, 10.1111/hae.12079
Aledort, 1994, A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group, J Intern Med, 236, 391, 10.1111/j.1365-2796.1994.tb00815.x
Tagliaferri, 2008, Effects of secondary prophylaxis started in adolescent and adult haemophiliacs, Haemophilia, 14, 945, 10.1111/j.1365-2516.2008.01791.x
World Federation of Hemophilia Diagnosis and management of inhibitors to factors VIII and IX: an introductory discussion for physicians Accessed May 30, 2013 Available from: http://www1.wfh.org/publication/files/pdf-1178.pdf
Kempton, 2012, Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A, Am J Hematol, 87, 933, 10.1002/ajh.23269
Gouw, 2007, Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study, Blood, 109, 4648, 10.1182/blood-2006-11-056291
Powell, 2007, Liposomal approach towards the development of a longer-acting factor VIII, Haemophilia, 13, 23, 10.1111/j.1365-2516.2007.01502.x
Kaufman, 1998, Can we improve on nature? “Super molecules” of factor VIII, Haemophilia, 4, 370, 10.1046/j.1365-2516.1998.440370.x
Gale, 2003, An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa, J Thromb Haemost, 1, 1966, 10.1046/j.1538-7836.2003.00348.x
Gale, 2006, Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants, J Thromb Haemost, 4, 1315, 10.1111/j.1538-7836.2006.01951.x
Ivens, 2013, PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers, Haemophilia, 19, 11, 10.1111/j.1365-2516.2012.02931.x
Mei, 2010, Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment, Blood, 116, 270, 10.1182/blood-2009-11-254755
Kaufman, 2013, Molecular approaches for improved clotting factors for hemophilia, Hematology Am Soc Hematol Educ Program, 2013, 30, 10.1182/asheducation-2013.1.30
Metzner, 2009, Genetic fusion to albumin improves the pharmacokinetic properties of factor IX, Thromb Haemost, 102, 634, 10.1160/TH09-04-0255
Peters, 2010, Prolonged activity of factor IX as a monomeric Fc fusion protein, Blood, 115, 2057, 10.1182/blood-2009-08-239665
Roopenian, 2007, FcRn: the neonatal Fc receptor comes of age, Nat Rev Immunol, 7, 715, 10.1038/nri2155
Coyle, 2012, Abstract FP-MO-03.2-3: An open-label phase I study to evaluate the pharmacokinetics and safety profile of Bay 94-9027, a PEGylated B-domain-deleted recombinant factor VIII, in previously treatment patients with severe hemophilia A, Haemophilia, 18, 22
Turecek, 2012, BAX 855, a PEGylated rFVIII product with prolonged half-life: development, functional and structural characterisation, Hamostaseologie, 32, S29, 10.1055/s-0037-1619772
Tiede, 2013, Enhancing the pharmacokinetic properties of recombinant factor VIII: first in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A, J Thromb Haemost, 11, 670, 10.1111/jth.12161
Thim, 2010, Purification and characterization of a new recombinant factor VIII (N8), Haemophilia, 16, 349, 10.1111/j.1365-2516.2009.02135.x
Powell, 2012, Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients, Blood, 119, 3031, 10.1182/blood-2011-09-382846
Agerso, 2012, Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs, Haemophilia, 18, 941, 10.1111/j.1365-2516.2012.02896.x
Martinowitz, 2011, Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) – an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A, Haemophilia, 17, 854, 10.1111/j.1365-2516.2011.02495.x
Peters, 2013, Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein, J Thromb Haemost, 11, 132, 10.1111/jth.12076
Dumont, 2012, Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs, Blood, 119, 3024, 10.1182/blood-2011-08-367813
Durocher, 2009, Expression systems for therapeutic glycoprotein production, Curr Opin Biotechnol, 20, 700, 10.1016/j.copbio.2009.10.008
Walsh, 2010, Post-translational modifications of protein biopharmaceuticals, Drug Discov Today, 15, 773, 10.1016/j.drudis.2010.06.009
Swiech, 2012, Human cells: new platform for recombinant therapeutic protein production, Protein Expr Purif, 84, 147, 10.1016/j.pep.2012.04.023
Zhang, 2012, Enzymatic release and detection of galactose-alpha-1,3-galactose (a-Gal) in recombinant FVIII products, Haemophilia, 18, PO
Ghaderi, 2012, Production platforms for biotherapeutic glycoproteins. occurence, impact, and challenges of non-human sialylation, Biotechnol Genet Eng Rev, 28, 147, 10.5661/bger-28-147
Lenting, 2007, Clearance mechanisms of von Willebrand factor and factor VIII, J Thromb Haemost, 5, 1353, 10.1111/j.1538-7836.2007.02572.x
Suiter, 2010, Recombinant human von Willebrand factor (rVWF): First-in-human study evaluating pharmacokinetics, demonstrating safety and tolerability in type 3 von Willebrand disease [abstract], Blood (ASH Annual Meeting Abstracts), 116, 237
Bjorkman, 2012, Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight, Blood, 119, 612, 10.1182/blood-2011-07-360594
Ljung, 2013, Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients, Haemophilia, 19, 481, 10.1111/hae.12094
Lindvall, 2012, Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy, Haemophilia, 18, 855, 10.1111/j.1365-2516.2012.02879.x
Lencer, 2005, A passionate kiss, then run: exocytosis and recycling of IgG by FcRn, Trends Cell Biol, 15, 5, 10.1016/j.tcb.2004.11.004
Ghetie, 2000, Multiple roles for the major histocompatibility complex class I- related receptor FcRn, Annu Rev Immunol, 18, 739, 10.1146/annurev.immunol.18.1.739
McGarry, 1983, Intracellular distribution and degradation of immunoglobulin G and immunoglobulin G fragments injected into HeLa cells, J Cell Biol, 96, 338, 10.1083/jcb.96.2.338